TriSalus Life Sciences (NASDAQ:TLSI) Posts Quarterly Earnings Results, Meets Expectations

TriSalus Life Sciences (NASDAQ:TLSI) released its earnings results on Thursday. The company reported ($0.35) EPS for the quarter, hitting the consensus estimate of ($0.35), Zacks reports. The business had revenue of $8.26 million for the quarter, compared to analyst estimates of $8.12 million. TriSalus Life Sciences updated its FY 2025 guidance to EPS.

TriSalus Life Sciences Trading Down 1.4 %

Shares of TLSI opened at $5.50 on Friday. The stock has a 50 day moving average of $5.39 and a 200 day moving average of $4.73. The company has a market capitalization of $167.71 million, a price-to-earnings ratio of -2.21 and a beta of 0.48. TriSalus Life Sciences has a 12 month low of $3.50 and a 12 month high of $10.42.

Insiders Place Their Bets

In other news, CEO Mary T. Szela acquired 4,826 shares of TriSalus Life Sciences stock in a transaction on Monday, January 27th. The stock was acquired at an average cost of $5.42 per share, with a total value of $26,156.92. Following the completion of the acquisition, the chief executive officer now owns 429,503 shares in the company, valued at approximately $2,327,906.26. This trade represents a 1.14 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Sean Murphy bought 15,000 shares of the firm’s stock in a transaction on Monday, January 27th. The stock was purchased at an average cost of $5.31 per share, with a total value of $79,650.00. Following the completion of the transaction, the insider now directly owns 182,732 shares of the company’s stock, valued at approximately $970,306.92. The trade was a 8.94 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 54,856 shares of company stock valued at $294,608. Insiders own 32.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on TLSI shares. Cantor Fitzgerald started coverage on TriSalus Life Sciences in a report on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 target price on the stock. Roth Mkm reiterated a “buy” rating and set a $11.00 price objective on shares of TriSalus Life Sciences in a report on Friday, January 24th. Finally, Lake Street Capital assumed coverage on shares of TriSalus Life Sciences in a report on Thursday, February 13th. They issued a “buy” rating and a $10.00 target price on the stock. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $11.56.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.